Shanghai Fosun Pharmaceutical (02196): FXB0871 approved for clinical trials in locally advanced or metastatic solid tumors.

Shanghai Fosun Pharmaceutical (02196) announced recently that its subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (hereinafter referred to as "Shanghai Fosun Pharmaceutical Industry") has received approval from the National Medical Products Administration to conduct clinical trials for FXB0871 in the treatment of advanced or metastatic solid tumors. Shanghai Fosun Pharmaceutical Industry plans to conduct Phase I clinical studies of the drug in China once the necessary conditions are met. FXB0871 is a PD-1 targeted IL-2 fusion protein developed through a collaboration between the group (including the company and its subsidiaries/units, hereinafter referred to as the same) and Teva Pharmaceutical Industries Ltd. (hereinafter referred to as "Teva"), with the group holding exclusive development, production, and commercialization rights in China and certain designated Southeast Asian countries and regions. FXB0871 selectively delivers de-toxified interleukin-2 (IL-2) to T cells expressing PD-1 in the tumor microenvironment, enhancing T cell activity and reducing systemic toxicity. As of the date of this announcement (March 31, 2026), Teva is conducting international Phase I clinical studies of the drug (designated as TEV-56278 by Teva) in the United States and Canada. As of February 2026, the group's cumulative research and development investment in FXB0871 is approximately RMB 6.28 million (unaudited). As of the date of this announcement, there are no approved anti-PD1-IL2 dual targeting drugs on the market worldwide.